On the stock market since 2011, it operates in the world of health and science. It has 30,207 employees. Now — the numbers.
This is an established company with proven profits.
Average growth of 13% a year over the last 4 years. Every year shown ended in profit.
The gap is $148B. In times of high interest rates, a gap like that can squeeze a company.
The stock trades 44% below its peak. The market has trimmed its expectations for the company.
Over the last 3 years, sales grew about 12% a year on average.
It pays out $0.20 per share each year — regular cash for whoever holds the stock.
Nothing in the current numbers stands out as a clear risk. Still, no stock is ever risk-free.
On our five-subject report card, TRUMF sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: TRUMF is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.